Drug General Information |
Drug ID |
D0MU0S
|
Former ID |
DNC000602
|
Drug Name |
EM-800
|
Drug Type |
Small molecular drug
|
Indication |
Estrogen deficiency [ICD10:E28.39]
|
Discontinued in Phase 3 |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C39H47NO6
|
Canonical SMILES |
CC1=C(C(OC2=C1C=CC(=C2)OC(=O)C(C)(C)C)C3=CC=C(C=C3)OCCN<br />4CCCCC4)C5=CC=C(C=C5)OC(=O)C(C)(C)C
|
InChI |
1S/C39H47NO6/c1-26-32-20-19-31(45-37(42)39(5,6)7)25-33(32)46-35(34(26)27-11-17-30(18-12-27)44-36(41)38(2,3)4)28-13-15-29(16-14-28)43-24-23-40-21-9-8-10-22-40/h11-20,25,35H,8-10,21-24H2,1-7H3/t35-/m0/s1
|
InChIKey |
OEKMGABCSLYWOP-DHUJRADRSA-N
|
CAS Number |
CAS 182167-03-9
|
PubChem Compound ID |
|
PubChem Substance ID |
14838931, 14887663, 24163736, 45296209, 77523681, 93165513, 103260302, 103954838, 128797033, 135264126, 142213937, 227995016, 241178694
|
Target and Pathway |
Target(s) |
Estrogen receptor beta |
Target Info |
Antagonist |
[2]
|
Estrogen receptor |
Target Info |
Antagonist |
[2]
|
KEGG Pathway
|
Estrogen signaling pathway
|
Prolactin signaling pathwayhsa04915:Estrogen signaling pathway
|
Prolactin signaling pathway
|
Thyroid hormone signaling pathway
|
Endocrine and other factor-regulated calcium reabsorption
|
Proteoglycans in cancer
|
NetPath Pathway
|
FSH Signaling Pathway
|
EGFR1 Signaling Pathway
|
RANKL Signaling Pathway
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
Validated nuclear estrogen receptor beta network
|
Validated nuclear estrogen receptor alpha networksmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
|
Signaling events mediated by HDAC Class II
|
LKB1 signaling events
|
Regulation of Telomerase
|
ATF-2 transcription factor network
|
AP-1 transcription factor network
|
FOXM1 transcription factor network
|
Validated nuclear estrogen receptor alpha network
|
Signaling mediated by p38-alpha and p38-beta
|
FOXA1 transcription factor network
|
Reactome
|
Nuclear Receptor transcription pathwayR-HSA-1251985:Nuclear signaling by ERBB4
|
Nuclear Receptor transcription pathway
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Ovarian Infertility Genes
|
Integrated Pancreatic Cancer Pathway
|
Nuclear ReceptorsWP712:Estrogen signaling pathway
|
Nuclear Receptors Meta-Pathway
|
Estrogen Receptor Pathway
|
Signaling by ERBB4
|
JAK/STAT
|
Leptin signaling pathway
|
miR-targeted genes in muscle cell - TarBase
|
Integrated Breast Cancer Pathway
|
Nuclear Receptors
|
References |
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009862) |
---|
REF 2 | EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. Endocrinology. 1998 Jan;139(1):111-8. |